Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>
SOURCE  Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Z Trim Holdings, Inc. ... to a variety of industries, announced that Chef ... discussion at this year,s National Restaurant Association ("NRA") NRA ... behalf of the Research Chefs Association.  Chef Ryan spoke ... Good, the Bad and the Ugly," joining four other ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
Breaking Biology Technology:Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Mass., Jan. 13 Alseres Pharmaceuticals, Inc. (Nasdaq: ... entered into a securities purchase agreement (the "Agreement") with Robert ... stock of the Company at a purchase price of $1.00 ... of $1 million. In connection with the Agreement, Mr. ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... been granted its 31st U.S. Patent, # 7,476,382, ... patent includes claims to pharmaceutical compositions containing reovirus. ... proprietary position for REOLYSIN(R)," said Mary Ann Dillahunty, ...
... (TSX: GEN), a company focused on developing blood-based ... and personalized health management, today announced it has ... for the detection of Chagas disease related gene ... discovery of a blood biomarker-based method of testing ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 2
(Date:5/22/2013)... whole organism, as they may lead to life-threatening illnesses ... report how byproducts of respiration cause mispairing of subunits ... cells controls the form and function of every cell ... encoded in the linear sequence of the four subunits ... guanine (G) and thymine (T). Random changes in the ...
(Date:5/22/2013)... screening for prostate cancer could become as easy for ... to UC Irvine research published today in the ... more than a decade of work, UC Irvine chemists ... markers for prostate cancer in urine, meaning that the ... and at dramatically lower cost. The same technology could ...
(Date:5/21/2013)... Durham, NC Biologists have known for a long ... Exactly why isn,t well understood, particularly for plants. But ... Robert Lanfear of Australian National University and the U. ... study to be published 21 May in the journal ... shorter plants have faster-changing genomes. , Drawing from a ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Small but speedy: Short plants live in the evolutionary fast lane 2
... children with undiagnosed learning disorders, developmental deficits, and congenital ... which are explored in detail in a reflective article ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... of print at www.liebertpub.com/gtmb An ...
... solved an important mystery about why an arsenic compound, ... an effective therapeutic agent against disease and infections. According ... of Genetics ( http://www.genetics.org ) scientists from ... common water contaminant in many parts of the world, ...
... A new study conducted by a researcher at Ben-Gurion ... for Social Policy Studies in Israel reports that Israeli,s ... and residents of other OECD (Organization for Economic Cooperation ... data, from 2005, the average American life expectancy is ...
Cached Biology News:Unexplained childhood disorders 2Scientists solve mystery of arsenic compound 2Life expectancy higher in Israel than in US, according to Ben-Gurion U. researcher 2
... PolarScreen Progesterone Receptor (PR) Competitor ... or screening novel progesterone receptor binding ... homogenous assay utilizes a fusion of ... domain of human progesterone receptor [PR-LBD(GST)] ...
... organic acid analysis standard is ... organic salts; molecular weights range ... standard is provided for use ... and the organic acid analysis ...
... Eastman Kodak Companys Molecular Imaging ... KODAK Image Station 4000 Digital Imaging ... camera technology for comprehensive fluorescence, luminescence, ... systems 4 million pixel CCD and ...
... shape and size analyzer offering a wide dynamic ... simplicity in mind. It is comprised of a ... bench. The system is completely computer controlled. The ... applications such as dry or where smaller volumes ...
Biology Products: